K Pharma (4896) · InitiativeRestated
Research and development with external experts toward a company-sponsored clinical trial for chronic spinal cord injury
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Research and development toward preparing for company-sponsored clinical trials for chronic-phase spinal cord injuryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「For development pipelines including chronic spinal cord injury and chronic cerebral infarction, we will prepare for company-sponsored clinical trials in line with research and development progress and work to enter into joint research or license agreements with partners at an appropriate stage.」
The company continues its policy of preparing company-sponsored clinical trials for chronic spinal cord injury and other conditions and pursuing agreements with partners. - FY2023First statedAnnual report
「For the chronic spinal cord injury development pipeline, we entered into an advisory agreement with external experts in June 2023.」
The company entered into an advisory agreement with external experts for chronic spinal cord injury and is advancing research and development toward a company-sponsored clinical trial.